Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 16 AL 30

Towards Improved P2X7R Cellular Models for Alzheimer's Disease Drug Discovery

Agius CTA, McKenzie ADJ, Woollett K, Werry EL, Kassiou M.

ACS Chem Neurosci. 2026 Oct 7;17(19):3334-3350. doi: 10.1021/acschemneuro.6c00089.

Gut-brain axis in Alzheimer's disease: neuroinflammatory mechanisms and immunopharmacological interventions

Sharma R, Kumar G, Thakur A.

Inflammopharmacology. 2026 Oct 23. doi: 10.1007/s10787-026-02433-w. Online ahead of print.

Neuromodulatory interventions for Alzheimer's disease

Wang R, Zhu B, Guo Q, Huang JS, Zhang W.

Front Aging Neurosci. 2026 Oct 8;18:1925914. doi: 10.3389/fnagi.2026.1925914. eCollection 2026.

Therapeutic Potential of Marine Natural Products Against Alzheimer's Disease: Molecular Mechanisms, Druggability Evaluation and Clinical Translation Barriers

Huang D, Lu R, Sheng C, Zheng J, Wang Y, Sang Z.

Mar Drugs. 2026 Oct 10;24(10):356. doi: 10.3390/md24100356.

Synthetic Insights on Donepezil: An Anti-Alzheimer Drug

Khuman YM, Kapadiya YM, Maru JJ.

Arch Pharm (Weinheim). 2026 Oct;359(10):e70364. doi: 10.1002/ardp.70364.

Alpiniae oxyphyllae Fructus in Alzheimer's Disease: Multi-Target Mechanisms, Current Evidence, and Future AI-Driven Perspectives

Qin Q, Yan Q, Zhu K, Miao J, Yang M, Wu Z, Fan C, Jiang P, Wu G, Wang Q.

Molecules. 2026 Oct 14;31(20):3681. doi: 10.3390/molecules31203681.

Caregiver positivity as a psychosocial modifier of lecanemab-related outcomes in Alzheimer's disease: A multicenter longitudinal study in China

Wu W, Liu H, Liang Y, Li H, Zhang J, Sun Z, Song Y, Fei M, Wu H, Jiang M, Fan S, Zhou C, Cao Y, Chen H, Liu S.

Alzheimers Dement. 2026 Oct;22(10):e71894. doi: 10.1002/alz.71894.

TREM2 Signaling and Alzheimer's Disease: Experimental Modulators, Progress, and Challenges

Sayegh M, Azarfar K, Reyna EM, Kennedy JM, Sabbagh MN, Decourt B.

Drug Des Devel Ther. 2026 Oct 23;20:611558. doi: 10.2147/DDDT.S611558. eCollection 2026.

Efficacy and safety of donanemab in the European eligible population: TRAILBLAZER-ALZ 2 post-hoc analyses

Jessen F, Dell'Agnello G, Zimmer JA, Sapin C, Dichter S, Doty E, Epelbaum S, Evans CD, Hauck PM, Khanna R, Brooks DA, Sims JR, Agosta F; Alzheimer’s Disease Neuroimaging Initiative (ADNI).

J Prev Alzheimers Dis. 2026 Oct;13(8):100605. doi: 10.1016/j.tjpad.2026.100605. Epub 2026 May 27.

Appropriate use recommendations of the Spanish Society of Neurology's Behavioural Neurology and Dementia Study Group on anti-amyloid antibodies in the treatment of Alzheimer disease

Sánchez-Valle R, Alcolea D, Amer Ferrer G, Balasa M, Casado Naranjo I, Fortea J, Lladó A, Lleó A, Montes AM, Martinez Lozano L, Martínez-Lage P, Matias-Guiu JA, Mendioroz M, Perez Martinez DA, Ripoll GP, Riverol M, Sanchez-Juan P, Bondía HV; Spanish Society of Neurology’s Behavioural Neurology, Dementia Study Group working group for the appropriate use of anti-amyloid monoclonal antibody treatment.

Neurologia (Engl Ed). 2026 Oct;41(8):502075. doi: 10.1016/j.nrleng.2026.502075. Epub 2026 May 26.

Unveiling the pathogenesis and therapeutic strategies of Alzheimer's disease through cuproptosis

Xu S, Mu J, Wang Z, Yang J, Tian D, Shi T, Lan J, He P, Hao Z, Fu Y, Xing L, Ye J, Wang J.

Biometals. 2026 Oct;39(5):1361-1384. doi: 10.1007/s10534-026-00835-5. Epub 2026 Jun 18.

Regulation of different kinases for Alzheimer's disease therapy: progresses and perspectives

Han M, Liao Q, He S, Guo L, Lu Z, Wang X, Sun W, Duan Y, Lyu W, Li Q.

Bioorg Chem. 2026 Oct 5;181:110300. doi: 10.1016/j.bioorg.2026.110300. Epub 2026 Jul 25.

Pharmacological targeting of neuroimmune-synaptic interactions in Alzheimer's disease: Integrating NETosis, microglia, and synaptic vulnerability

Juanlu C, Chen LH.

Curr Opin Pharmacol. 2026 Oct;90:102650. doi: 10.1016/j.coph.2026.102650. Epub 2026 Jul 20.

Bypassing the bottleneck: Gamma-glutamylcysteine supplementation for brain glutathione enrichment in Alzheimer's disease

Mandal PK, Perry G, Maroon JC, Corby P, Patira R, Lopez OL.

J Alzheimers Dis. 2026 Oct;113(4):1626-1633. doi: 10.1177/13872877261474009. Epub 2026 Aug 13.

Allosteric modulation of ionotropic and G protein-coupled receptors in Alzheimer's disease: A neuroprotective strategy and therapeutic implications

Fereidouni A, Nematollahi S, Mathew KT, Favennec V, Liceran L, Aldenhoff-Kelly C, Valdivieso MA, Trent S, Moradikor N.

Int J Biol Macromol. 2026 Oct;379:154063. doi: 10.1016/j.ijbiomac.2026.154063. Epub 2026 Aug 14.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias